Allergan

Law360, Boston (March 20, 2018, 5:54 PM EDT) -- A class of purchasers of an anti-inflammatory drug made by Allergan PLC told the First Circuit on Tuesday that a Massachusetts federal judge was right to grant them class certification in their suit claiming the pharmaceutical company illegally stifled generic competition in ...

Today we're going to take a look at the well-established Allergan plc (NYSE:AGN). The company's stock saw a decent share price growth in the teens level on the NYSE over the last few months. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company's ...

Allergan ended 2017 facing heaps of criticism, with its ill-fated tribal licensing deal at the center. Shares were down. Job cuts were announced. But in spite of all that, its board felt Allergan did well enough to reward CEO Brent Saunders with a $32.8 million pay package—an eightfold increase over 2016.

“Allergan's abuse of the patent system in a really unique and first-of-its-kind deal warrants congressional oversight and action,” Association for Accessible Medicines (AAS) Vice President of Federal Affairs Erik Komendant told Bloomberg Law in an interview. “The decision by the company to appeal the ...

Allergan was blasted for its unusual Mohawk patent license, and now it's a total flop. by Eric Sagonowsky |. Feb 26, 2018 11:10am. Allergan's move to transfer patents to the Saint Regis Mohawk Tribe and license them back has come up short. (Image: Allergan). Share Facebook Twitter LinkedIn Email Print. After months of ...

New competition to its top product, Botox, and the surprise loss of patent exclusivity for its second biggest, the dry-eye treatment Restasis, have left investors with worry lines. Even after a recent mini-rally, shares of Allergan (ticker: AGN) are down about 50% from all-time highs of $340 in mid-2015, closing ...